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TSDiscussion
Dr. W.R. Smythe (Temple, Texas): Drs. Wright and Jones, mem-
bers, and guests:
Thanks for the opportunity to discuss this paper.
Pierre Denoix was a French pathologist who did the initial work
on the TNM staging system in the early 1940s. He was at the Na-
tional Institute of Hygiene there. What you may not know, actually,
is that not only do we have New York to thank for this group and all
of their contributions to thoracic surgery, but we also have New
York to thank for the TNM staging system in general, as the Na-
tional Institute of Hygiene was funded by the Rockefeller Founda-
tion of New York, allowing
Dr. Denoix to do his work.
It seems amazing to me that we have resisted for such a long time
the notion that mesothelioma is any different from any other tumor.
There are idiosyncrasies of this disease, but certainly tumor extent,
histologic type, and nodal status are just as important as they are for
breast cancer and for lung cancer, and that really shouldn’t come as
a surprise to us.
This work is really a continuation of the work been that has been
done by Dr. Rusch and her colleagues since the mid-1990s, and I
think now we have unequivocal proof that the TNM staging system
for this disease is useful and should be adhered to. And, as Dr. Gins-
berg said in 1995 when I was a fellow listening to Dr. Rusch make
one of the first presentations about this concept at this meeting that
we had 7 or 8 staging systems, we really should have one. I think that610 The Journal of Thoracic and Cardiovascular Surgery c Septhe proof is in the pudding now. The pudding is done. It’s time for us
just to have one staging system, and we appreciate your efforts.
I just have three questions. First, in considering the importance of
the sarcomatous histologic subtype in this disease, did you see any
difference in the metastatic patterns for sarcomatous versus epithe-
lial to the nodal stations, and if you did, are there any implications
for the staging system in regards to histologic type, knowing how
badly those patients do?
The second question is, if you’re suggesting that we should stage
patients at the N1 level, how do we do that? These lungs are often
encased in tumor. How do we convince our pathology colleagues
actually to dissect these nodes out of these lungs that are so heavily
encased with disease in the fissure, disease that often travels up the
bronchus into the hilum?
Lastly, now that we know the importance of N2 disease, and,
again, it has been shown by many groups, including yours and
ours in Texas and so forth, how do we clinically stage these patients
for N2 disease, especially in locations that are extratracheal loca-
tions, like levels 8, 9, and the internal mammary chain? I think there
were 79 patients in your study that had disease in these areas. If you
only have disease in these areas, how do you clinically stage the pa-
tients before surgery? The tumor oftentimes is adjacent to the nodes.
It’s difficult to discern the node from the tumor in regards to PET
scanning. And in our experience in Texas, we found that regardless
of nodal size, even a 3 mm lymph node at levels 8, 9, and the internal
mammary chain can harbor tumor. How do we clinically stage these
patients and make good decisions about who to operate on and who
not to operate on in regards to their stage?
Again, thanks for the opportunity. It was a great paper. Thanks
for giving me the paper ahead of time. It was very well written, suc-
cinct, and clear. I appreciate it.
Dr. Flores: With regard to the first question about the differences
in nodal spread based on histology, we have found a decent amount
of nodal disease in patients who have had sarcomatoid and mixed
tumors. However, the numbers of sarcomatoid patients are very,
very small. The mixed tumors tend to spread to the nodal stations
in a similar way as the epithelioid patients. The sarcomatoid pa-
tients, while there were some metastases, the numbers are too small
to make any dramatic conclusions from.
As far as the N1 dissection is concerned, when we have extrap-
leural patients, our pathologists do get in there and follow the bron-
chus down and get the multiple nodal stations from the N1 levels.
Our main point with this paper was we took it for granted that,
you know, you do a mediastinal nodal dissection when you do
a pleurectomy, and until we did this paper, we realized we weren’t
staging the N1 nodes at the time of pleurectomy. So now it will be
our routine to go ahead if we’re doing a pleurectomy to try and get
the level 10 nodes out, et cetera.
As far as clinically staging these patients, it’s quite difficult, as
you pointed out, where you have the pleural rind and right near
that pleural rind is a level 7 node or a level 8 or 9 node, and it’s
very difficult to tell whether you’re hitting the node or whether
you’re hitting tumor regardless of whether you’re doing it by endo-
scopic ultrasound or endobronchial ultrasound. Although I think
those roles will come into play later on down the line, it’s a difficult
problem and I don’t think we’ll be able to understand that. Right
now the best tools that we have for preoperative staging are CAT
scan and PET scan together, and that’s about it.tember 2008
